How many drugs treat Eosinophilic asthma?

Drug Landscape tracks 7 marketed treatments for Eosinophilic asthma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/eosinophilic-asthma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Eosinophilic asthma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eosinophilic asthma (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Eosinophilic asthma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fasenra	BENRALIZUMAB	AstraZeneca	Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]	Interleukin-5 receptor subunit alpha	2017-01-01
Cinqair	RESLIZUMAB	Teva Respiratory Llc	Interleukin-5 Antagonist [EPC]	Interleukin-5	2016-01-01
Nucala	MEPOLIZUMAB	GSK	Interleukin-5 Antagonist [EPC]	Interleukin-5	2015-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Caricide	DIETHYLCARBAMAZINE	Pfizer	Anthelmintic	Arachidonate 5-lipoxygenase	1950-01-01
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1
Nucala	Nucala	Mayo Clinic		Interleukin-5

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AstraZeneca · 1 drug in Eosinophilic asthma
GSK · 1 drug in Eosinophilic asthma
Generic (originally Schering) · 1 drug in Eosinophilic asthma
Hannover Medical School · 1 drug in Eosinophilic asthma
Mayo Clinic · 1 drug in Eosinophilic asthma
Pfizer · 1 drug in Eosinophilic asthma
Teva Respiratory Llc · 1 drug in Eosinophilic asthma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Eosinophilic asthma:

Cite this brief

Drug Landscape (2026). Eosinophilic asthma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/eosinophilic-asthma. Accessed 2026-06-10.

Eosinophilic asthma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing